Lonza Group AG (LONN.SW)

Swiss · Healthcare · Diagnostics & Research
651.20 CHF-2.37%As of 2026-11-22 · CHF
Last session low 649.00 CHFLast session high 670.00 CHF
52-week low 454.60 CHF52-week high 675.60 CHF
Market cap (USD)
$54.17B
Sector
Healthcare
P/E (TTM)
43.2x
Dividend yield
0.77%

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in CHF.

IndicatorValueReading
RSI (14)55.6In the neutral range (30 to 70)
MACD (12, 26, 9)15.20Below its signal line (18.31); histogram -3.11
Bollinger %B (20, 2)41%Inside the bands (630.12 to 681.92)
SMA 20656.02Price is 0.7% below
SMA 50608.42Price is 7.0% above
SMA 200544.98Price is 19.5% above
ATR (20)1.81% of priceAverage true range per day
52-week position89%In the upper part of the 454.60 to 675.60 range

About Lonza Group AG

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments.

Latest fiscal yearEnded 2025-12-31: revenue of 6.53B CHF and an operating margin of 20.8%.

More in Diagnostics & Research